R&D
Anticancer Drug/Personalized Anticancer Drug/Osteoarthritis/COPD/Neurodegenerative Diseases
Neurodegenerative
diseases
-
01
Alzheimer's
Disease
-
Alzheimer's disease was first identified by German neuropathologist Dr. Alois Alzheimer
in 1906. As the most common form of dementia, Alzheimer's disease accounts for
60-70% of total dementia cases.
-
In the absence of a cure, Alzheimer’s disease represents an area of the highest
unmet medical need.
-
There is a crucial need to develop therapeutics to treat Alzheimer's disease as
it would improve the quality of life for the elderly as well as alleviate exorbitant
socioeconomic burdens caused by a rapid increase in aging populations.
-
02
Therapeutics
Development
-
Nanosized stem cell-derived vesicles are a strong candidate for neurodegenerative disease
therapeutics because of their capability to penetrate the blood-brain barrier (BBB).
-
The neuroprotective effects of stem cell-derived vesicles were observed in
a dose-dependent manner in in vitro model of Alzheimer's disease.
-
The effects of stem cell-derived vesicle treatment in neuroprotection and neurogenesis
will be investigated using animal models of Alzheimer's disease.
This study is conducted in collaboration.